N-terminal telopeptide

In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a biomarker used to measure the rate of bone turnover. NTX can be measured in the urine or serum.^[1]

Usefulness of NTX as a biomarker

Evaluating an individual's rate of bone turnover, termed bone remodeling, directly may be important in assessing his or her potential nonsurgical treatment response as well as evaluating his or her risk of developing complications during healing following surgical intervention. To determine an individual's rate of bone turnover, numerous biomarkers are available in the body fluids that can be correlated to this rate, and one such biomarker is NTX.^[1]

However, while NTX does fluctuate in a very sensitive manner line with bone resorption patterns, they are not very specific, in that they may vary spontaneously without physiologic intervention. For example, NTX levels may drop by 50% from day to day with no treatment,^[2] thus, making NTX levels unconvincing evidence of treatment effect.^[3]

Conversely, the serum CTX biomarker, described in 2000 by Rosen, appears to be a much more effective and valuable indicator of bone resorption rate.^[3]

References

1. ^ ^{a b} Kousuke, I, et al. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment, J Orthop Sci 2008;13:438–441
2. ^ Rosen HN, et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphates. Calcif Tissue Int 1998;63:363–368
3. ^ ^{a b} Rosen HN, et al. Serum CTX. A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100